ALS patients contend with $158K price tag on new drug WASHINGTON (AP) — For two years, Becky Mourey pushed the Food and Drug Administration to approve an experimental drug for her Lou Gehrig’s disease.Patients with insurance coverage say the $158,000 per year price tag set by drugmaker Amylyx Pharmaceutical is fueling insurance delays or denials, and sometimes exorbitant out-of-pocket expenses.“They could cut the price in half and still make a hefty profit.” 2 COVID-19 deaths reported in Beijing as virus surges UK sending 1,200 troops to fill in as ambulance crews strike Want to email your doctor?Under the federal program, he would likely owe $7,400 in copays for Relyvrio before reaching his out-of-pocket maximum.Dr. Terry Heiman-Patterson, a neurologist at Temple University, says it’s taken about four to six hours of phone calls with insurers to get each new patient on Relyvrio."